- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
AI Tool That Helps Visualize Prostate Cancer Now in Clinic
The FDA granted 510(k) clearance to Unfold AI, which was formerly known as iQuest, in December 2022.
Unfold AI, an artificial intelligence (AI)–powered software application program for the management of patients with prostate cancer, is being used with patients for the first time in a commercial setting, according to Avenda Health, the developer of the technology.1
"I am hopeful that Unfold AI will be to intraprostatic staging what prostate-specific membrane antigen PET-CT has been for extraprostatic staging,” stated Wayne Brisbane, MD, an assistant professor of urology at UCLA Health, and one of the initial physicians using the technology, in a press release.
The FDA granted 510(k) clearance to Unfold AI, which was formerly known as iQuest, in December 2022.2 Physicians are now using the technology to work with patients on treatment selection and establishing an optimal overall management plan.
Unfold AI visualization. Image credit: Avenda Health
According to Avenda, Unfold AI “combines patient-specific data from prostate imaging, biopsies, and pathology into deep-learning algorithms to create a unique and tailored cancer estimation map. Its 3D, AI-generated map visualizes the location of the cancer for physicians to use in treatment decision making and interventional planning.”
"With a wide breadth of ablative options available, Unfold AI represents the first technology to improve tumor localization and patient selection," noted Brisbane.
Avenda reported in the release that Unfold AI has been validated in multiple clinical studies. For example, clinical data shared during the 2022 American Urological Association (AUA) Annual Meeting showed that Unfold AI improved the establishment of tumor margins over conventional treatment planning from 56 percent to 80 percent.3
"This is a major step forward for the prostate cancer community and we are beyond thrilled to see a decade of hard work and research pay off," Leonard Marks, MD, co-founder and chief medical officer of Avenda Health, stated in a press release. "Our mission at Avenda Health is to create a better quality of life for prostate cancer patients and to give urologists a clearer view of the cancer so we can better treat our patients. Unfold AI will improve clinical care and decision making."
References
1. Avenda Health. Avenda Health announces first commercial use of Unfold AI on prostate cancer patients in the U.S. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-health-announces-first-commercial-use-of-unfold-ai-on-prostate-cancer-patients-in-the-us-301806285.html . Published April 25, 2023. Accessed April 27, 2023.
2. Hall J. Could an emerging AI platform supplant traditional MRI for assessing prostate cancer? Diagnostic Imaging. Available at https://www.diagnosticimaging.com/view/could-an-emerging-ai-platform-supplant-traditional-mri-for-assessing-prostate-cancer- . Published December 7, 2022. Accessed April 27, 2023.
3. Avenda Health. Avenda Health receives FDA Investigational Device Exemption for AI-enabled prostate cancer therapy. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-health-receives-fda-investigational-device-exemption-for-ai-enabled-prostate-cancer-therapy-301602061.html . Published August 9, 2022. Accessed April 27, 2023.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
January 4th 2025In patients with high-risk, hormone sensitive prostate cancer who had no evidence of metastasis on conventional imaging, PSMA PET revealed polymetastatic disease in 24 percent of patients and M1 disease staging in 46 percent of patients.
Can MRI and Micro-Ultrasound Guidance Bolster Focal Laser Ablation Outcomes for Prostate Cancer?
January 3rd 2025For patients with localized prostate cancer and PI-RADS 3 or higher lesions, MRI-guided micro-ultrasound multifiber focal laser ablation had an 18 percent recurrence rate at one year, according to newly published research.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
